Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia

Garry M. Marley, M. Craig Miller, Michael W. Kattan, Gang Zhao, Kevin P. Patton, Robert L. Vessella, George L. Wright, Paul F. Schellhammer, Robert W. Veltri

Research output: Contribution to journalArticle

Abstract

Objectives. Ratios of free to total prostate-specific antigen (f/t PSA ratio) improved differentiation of benign prostatic hyperplasia (BPH) from prostate cancer (CaP). Using sera obtained at least 1 month prior to biopsy- confirmed diagnosis and logistic regression adjusted for disease prevalence, probability curves are constructed to predict the presence of CaP. Methods. The patient population included 122 (44%) BPH sera and 155 (56%) prostate carcinoma sera collected prior to any therapy. The total PSA range = 2.0- 20.0 ng/mL; median age = 69 years. External reference standards for both free and total PSA assays were used to standardize the assays and correct the ratio. Probability curves and tables for cancer incidence were formulated for a subset of the total test population (total PSA range = 2.0-10.0 ng/mL; 98 BPH, 118 CaP patients) by using logistic regression and prior cancer prevalence statistics derived from a published patient screening study. Results. Median f/t PSA ratios were 0.18 and 0.12 in the overall sample and 0.19 and 0.12 in the subset for BPH and CaP, respectively (P = 0.0001). The median total PSA concentrations for BPH and CaP were 5.8 and 6.7 ng/mL when total PSA range = 2.0-20.0 ng/mL and were 4.9 and 5.9 ng/mL when total PSA range = 2.0-10.0, respectively. Conclusions. Cancer probability curves were constructed to help guide decisions concerning biopsy and other aspects of prostate cancer disease management. Further validation of this approach in another series of patients is necessary and is planned.

Original languageEnglish (US)
Pages (from-to)16-22
Number of pages7
JournalUrology
Volume48
Issue number6 SUPPL.
DOIs
StatePublished - Dec 1996
Externally publishedYes

Fingerprint

Prostatic Hyperplasia
Prostate-Specific Antigen
Prostatic Neoplasms
Serum
Logistic Models
Biopsy
Neoplasms
Disease Management
Population
Prostate
Carcinoma
Incidence

ASJC Scopus subject areas

  • Urology

Cite this

Marley, G. M., Miller, M. C., Kattan, M. W., Zhao, G., Patton, K. P., Vessella, R. L., ... Veltri, R. W. (1996). Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia. Urology, 48(6 SUPPL.), 16-22. https://doi.org/10.1016/S0090-4295(96)00605-X

Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia. / Marley, Garry M.; Miller, M. Craig; Kattan, Michael W.; Zhao, Gang; Patton, Kevin P.; Vessella, Robert L.; Wright, George L.; Schellhammer, Paul F.; Veltri, Robert W.

In: Urology, Vol. 48, No. 6 SUPPL., 12.1996, p. 16-22.

Research output: Contribution to journalArticle

Marley, GM, Miller, MC, Kattan, MW, Zhao, G, Patton, KP, Vessella, RL, Wright, GL, Schellhammer, PF & Veltri, RW 1996, 'Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia', Urology, vol. 48, no. 6 SUPPL., pp. 16-22. https://doi.org/10.1016/S0090-4295(96)00605-X
Marley, Garry M. ; Miller, M. Craig ; Kattan, Michael W. ; Zhao, Gang ; Patton, Kevin P. ; Vessella, Robert L. ; Wright, George L. ; Schellhammer, Paul F. ; Veltri, Robert W. / Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia. In: Urology. 1996 ; Vol. 48, No. 6 SUPPL. pp. 16-22.
@article{a8d1dbb9b23b4a2b9ed52004229b9b93,
title = "Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia",
abstract = "Objectives. Ratios of free to total prostate-specific antigen (f/t PSA ratio) improved differentiation of benign prostatic hyperplasia (BPH) from prostate cancer (CaP). Using sera obtained at least 1 month prior to biopsy- confirmed diagnosis and logistic regression adjusted for disease prevalence, probability curves are constructed to predict the presence of CaP. Methods. The patient population included 122 (44{\%}) BPH sera and 155 (56{\%}) prostate carcinoma sera collected prior to any therapy. The total PSA range = 2.0- 20.0 ng/mL; median age = 69 years. External reference standards for both free and total PSA assays were used to standardize the assays and correct the ratio. Probability curves and tables for cancer incidence were formulated for a subset of the total test population (total PSA range = 2.0-10.0 ng/mL; 98 BPH, 118 CaP patients) by using logistic regression and prior cancer prevalence statistics derived from a published patient screening study. Results. Median f/t PSA ratios were 0.18 and 0.12 in the overall sample and 0.19 and 0.12 in the subset for BPH and CaP, respectively (P = 0.0001). The median total PSA concentrations for BPH and CaP were 5.8 and 6.7 ng/mL when total PSA range = 2.0-20.0 ng/mL and were 4.9 and 5.9 ng/mL when total PSA range = 2.0-10.0, respectively. Conclusions. Cancer probability curves were constructed to help guide decisions concerning biopsy and other aspects of prostate cancer disease management. Further validation of this approach in another series of patients is necessary and is planned.",
author = "Marley, {Garry M.} and Miller, {M. Craig} and Kattan, {Michael W.} and Gang Zhao and Patton, {Kevin P.} and Vessella, {Robert L.} and Wright, {George L.} and Schellhammer, {Paul F.} and Veltri, {Robert W.}",
year = "1996",
month = "12",
doi = "10.1016/S0090-4295(96)00605-X",
language = "English (US)",
volume = "48",
pages = "16--22",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6 SUPPL.",

}

TY - JOUR

T1 - Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia

AU - Marley, Garry M.

AU - Miller, M. Craig

AU - Kattan, Michael W.

AU - Zhao, Gang

AU - Patton, Kevin P.

AU - Vessella, Robert L.

AU - Wright, George L.

AU - Schellhammer, Paul F.

AU - Veltri, Robert W.

PY - 1996/12

Y1 - 1996/12

N2 - Objectives. Ratios of free to total prostate-specific antigen (f/t PSA ratio) improved differentiation of benign prostatic hyperplasia (BPH) from prostate cancer (CaP). Using sera obtained at least 1 month prior to biopsy- confirmed diagnosis and logistic regression adjusted for disease prevalence, probability curves are constructed to predict the presence of CaP. Methods. The patient population included 122 (44%) BPH sera and 155 (56%) prostate carcinoma sera collected prior to any therapy. The total PSA range = 2.0- 20.0 ng/mL; median age = 69 years. External reference standards for both free and total PSA assays were used to standardize the assays and correct the ratio. Probability curves and tables for cancer incidence were formulated for a subset of the total test population (total PSA range = 2.0-10.0 ng/mL; 98 BPH, 118 CaP patients) by using logistic regression and prior cancer prevalence statistics derived from a published patient screening study. Results. Median f/t PSA ratios were 0.18 and 0.12 in the overall sample and 0.19 and 0.12 in the subset for BPH and CaP, respectively (P = 0.0001). The median total PSA concentrations for BPH and CaP were 5.8 and 6.7 ng/mL when total PSA range = 2.0-20.0 ng/mL and were 4.9 and 5.9 ng/mL when total PSA range = 2.0-10.0, respectively. Conclusions. Cancer probability curves were constructed to help guide decisions concerning biopsy and other aspects of prostate cancer disease management. Further validation of this approach in another series of patients is necessary and is planned.

AB - Objectives. Ratios of free to total prostate-specific antigen (f/t PSA ratio) improved differentiation of benign prostatic hyperplasia (BPH) from prostate cancer (CaP). Using sera obtained at least 1 month prior to biopsy- confirmed diagnosis and logistic regression adjusted for disease prevalence, probability curves are constructed to predict the presence of CaP. Methods. The patient population included 122 (44%) BPH sera and 155 (56%) prostate carcinoma sera collected prior to any therapy. The total PSA range = 2.0- 20.0 ng/mL; median age = 69 years. External reference standards for both free and total PSA assays were used to standardize the assays and correct the ratio. Probability curves and tables for cancer incidence were formulated for a subset of the total test population (total PSA range = 2.0-10.0 ng/mL; 98 BPH, 118 CaP patients) by using logistic regression and prior cancer prevalence statistics derived from a published patient screening study. Results. Median f/t PSA ratios were 0.18 and 0.12 in the overall sample and 0.19 and 0.12 in the subset for BPH and CaP, respectively (P = 0.0001). The median total PSA concentrations for BPH and CaP were 5.8 and 6.7 ng/mL when total PSA range = 2.0-20.0 ng/mL and were 4.9 and 5.9 ng/mL when total PSA range = 2.0-10.0, respectively. Conclusions. Cancer probability curves were constructed to help guide decisions concerning biopsy and other aspects of prostate cancer disease management. Further validation of this approach in another series of patients is necessary and is planned.

UR - http://www.scopus.com/inward/record.url?scp=0030462120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030462120&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(96)00605-X

DO - 10.1016/S0090-4295(96)00605-X

M3 - Article

VL - 48

SP - 16

EP - 22

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6 SUPPL.

ER -